Bioventus (NASDAQ:BVS) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Bioventus (NASDAQ:BVS) released its quarterly earnings data on Wednesday. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06, FiscalAI reports. The company had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 30.75% and a net margin of 4.94%. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

• Strong Q1 results — revenue $132M (+7%), Adjusted EBITDA $24M (+24%), and Adjusted EPS $0.15 (nearly double); company raised 2026 Adjusted EPS and cash-from-operations guidance and reaffirmed revenue guidance of $600–$610M.
• The company is accelerating investment in four growth drivers (PNS, PRP, Ultrasonics, International), with PNS receiving more than half of planned spend and a dedicated general manager (Megan Rosengarten) hired to scale the PNS business.
• Cash generation and balance sheet progress — cash from operations increased by ~$28M YoY, debt was reduced by $22M to $272M, and management expects net leverage <2x by end of Q2 2026, prioritizing debt paydown and capital optionality.
• Margin and earnings resilience — adjusted gross margin of 76% (+110 bps) and adjusted EBITDA margin of 18% (+260 bps); management expects to hold ~20% adjusted EBITDA margin for 2026 despite stepped-up investments.
• Q1 benefited from a one-time favorable rebate adjustment (and ~+$2M FX tailwind); management calls the rebate timing idiosyncratic and did not raise full-year revenue guidance, signaling some of the quarter’s upside may not recur.

Bioventus Price Performance

Shares of BVS stock traded down $0.06 during trading on Friday, hitting $10.60. The company had a trading volume of 155,831 shares, compared to its average volume of 377,070. The stock’s 50-day moving average is $9.32 and its two-hundred day moving average is $8.22. The stock has a market capitalization of $881.03 million, a price-to-earnings ratio of 25.83 and a beta of 0.72. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. Bioventus has a 52 week low of $5.81 and a 52 week high of $11.25.

Analyst Ratings Changes

A number of research firms have weighed in on BVS. Barrington Research upped their price target on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. CJS Securities began coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price on the stock. Craig Hallum raised their price target on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $14.00.

Insider Transactions at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares of the company’s stock, valued at $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.00% of the stock is currently owned by insiders.

Institutional Trading of Bioventus

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Bioventus by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Bioventus by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after purchasing an additional 26,103 shares in the last quarter. Legal & General Group Plc increased its position in shares of Bioventus by 100.9% during the 2nd quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after purchasing an additional 35,873 shares during the last quarter. Rhumbline Advisers lifted its position in Bioventus by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after buying an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Bioventus by 32.5% in the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after buying an additional 51,951 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.